Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (1y) (2018 - 2024)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (1y) (2018 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 17.76% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -38.91% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -63.37% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 93.04% |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 34.31% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 128.45% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 186.95% |
| Dec 31, 2023 | 45.36% |
| Sep 30, 2023 | 75.44% |
| Jun 30, 2023 | 127.70% |
| Mar 31, 2023 | -8,807.33% |
| Dec 31, 2022 | 1,809.09% |
| Sep 30, 2022 | 985.17% |
| Jun 30, 2022 | 145.47% |
| Mar 31, 2022 | -75.78% |
| Dec 31, 2021 | -159.75% |
| Sep 30, 2021 | 229.37% |
| Jun 30, 2021 | 9.75% |
| Mar 31, 2021 | -31.48% |
| Dec 31, 2020 | 54.68% |
| Sep 30, 2020 | -146.28% |
| Jun 30, 2020 | 111.94% |
| Mar 31, 2020 | 156.18% |
| Dec 31, 2019 | 111.34% |
| Sep 30, 2019 | 59.06% |
| Jun 30, 2019 | 1,884.80% |